N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=42 Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
DCIS
Primary: Number of Participants With a Change in Ki-67 Level — 15; 5; 3 Participants — p=0.004
Phase 2 N=71 Orteronel as Monotherapy in Patients With Metastatic Breast Cancer (MBC) That Expresses the Androgen Receptor (AR)
Metastatic Breast Cancer
Primary: Response Rate (RR) — 4.8; 0 percentage of participants
Phase 2 N=76 Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall Disease
Breast Cancer · Chest Wall Disease
Primary: Disease Control Rate (DCR) at 18 Weeks — 20; 17 percentage of participants
Early Phase 1 N=20 Cabergoline in Metastatic Breast Cancer
Recurrent Breast Cancer · Stage IV Breast Cancer
Primary: Overall Response Rate (ORR) at 2 Months — 0 Participants
Phase 2 N=12 Hybrid Molecular Imaging of ER in Breast Cancer Patients With DCIS
Breast Cancer · Ductal Carcinoma in Situ - Category
Primary: 18F-FES Uptake in DCIS — 1.43 SUV
Phase 2 N=108 Letrozole in Treating Postmenopausal Women With Ductal Carcinoma in Situ
Breast Cancer
Primary: Mean Total MRI Functional Tumor Volume (FTV) Change From Baseline to Month 3 (V3) — -1.93 cubic centimeters — p=<0.001
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
N/A N=20 Phase IV Trial to Evaluate Breast Brachytherapy Using the Mammosite-Ml®
Breast Cancer · Ductal Carcinoma in Situ
Primary: Ipsilateral Recurrence Rate — 0 participants
Phase 2 N=79 Tamoxifen or Letrozole in Treating Women With Ductal Carcinoma in Situ
Breast Cancer
Primary: Median Change in 6-month Tumor Volume Compared to Baseline Using Mammography — -5.0 change in tumor volume (mm) — p=0.07
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
N/A N=20 Tactile Breast Imaging Sensor for Tumor Malignancy Characterization
Breast Cancer
Primary: Size Error in Millimeters — 0 milimeters
N/A N=1,007 Magnetic Resonance Imaging in Women Recently Diagnosed With Unilateral Breast Cancer
Breast Cancer · Contralateral Breast Cancer
Primary: MRI Diagnostic Yield of Cancers in the Contralateral Breast — 30; 114; 3; 822 Participants
Phase 2 N=24 SV-BR-1-GM in Metastatic or Locally Recurrent Breast Cancer
Breastcancer · Breast Neoplasm
Primary: Number of Patients With Treatment Emergent Adverse Events Occurring in Two or More Patients [Safety] — 24; 11; 8; 7 Participants
Phase 2 N=30 Denosumab and MRI Breast Imaging
Breast Cancer
Primary: Relative Change of ≥ 5% in Breast Density at 6 Months — 13; 8; 4 Participants — p=0.026
Phase 2 N=133 MammoSite as Sole Radiation Therapy Technique for Ductal Carcinoma In-Situ
DCIS
Primary: Local Control Rate for Follow-up Period of 5 Years. — 99 percentage of subjects
N/A N=1,638 Low Dose Molecular Breast Imaging as a Screening Tool for Women With Dense Breasts
Breast Cancer
Primary: Cancer Detection Rate Per 1000 Women Screened, by Breast Density — 3.2; 12.0; 10.7; 0 cancers per 1000 women screened — p=<0.001
N/A N=2,978 Molecular Breast Imaging and Digital Breast Tomosynthesis in Screening Patients With Dense Breast Tissue
Breast Carcinoma
Primary: Rate of Detection of Invasive Cancers — 9; 14 Participants
Phase 2 N=26 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
Phase 3 N=2,980 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Breast Cancer
Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33
Phase 2 N=27 4-Hydroxytamoxifen or Tamoxifen Citrate in Treating Women With Newly Diagnosed Ductal Breast Carcinoma in Situ
Ductal Breast Carcinoma in Situ · Estrogen Receptor-positive Breast Cancer
Primary: Difference Between Ki-67 Labeling Index in Tissue Samples Taken at Baseline and Post-treatment — -3.4; -5.1 percentage of 300 DCIS cells
Phase 2 N=103 Ixabepilone + Carboplatin Metastatic Breast Cancer
Metastatic Breast Cancer
Primary: Objective Response Rate (ORR) — 30.4; 34 percentage of participants
Phase 2 N=102 Cetuximab + / - Carboplatin for Estrogen Receptor-Negative, Progesterone Receptor-Negative Metastatic Breast Cancer
Breast Cancer
Primary: Overall Disease Response Rate — 0; 0; 1; 1 Participants
Phase 3 N=2,014 Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy
Breast Ductal Carcinoma In Situ
Primary: Ipsilateral Invasive Breast Cancer, Ipsilateral Skin Cancer Recurrence, or Ipsilateral DCIS-Free Survival — 95.1; 96.1 percentage of patients event free
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
N/A N=1 Prostate Cancer Screening in Men With Germline BRCA2 Mutations
Prostate Cancer
Primary: Number of Prostate Cancer Patients With BRCA2 Mutation Carriers — 0 participants
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
N/A N=1,232 Acquisition of Breast Mammography Images
Breast Cancer
Primary: Number of Participants for Whom Study Image Data Were Collected — 642; 124; 244 Participants
Phase 2 N=289 Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
Carcinoma
Primary: Overall Survival — 13.43; 7.62 months
N/A N=580 An Observational Study on Human Epidermal Growth Factor Receptor (HER) 2 Status of Breast Invasive Carcinoma in Latin American Participants
Breast Cancer
Primary: Percentage of Participants With Human Epidermal Growth Factor Receptor 2 (HER2) Status in Breast Cancer Specimens Using Immunohistochemistry (IHC) and Silver In-Situ…